145 related articles for article (PubMed ID: 15163168)
1. Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer.
Wist EA; Sommer HH; Ostenstad B; Risberg T; Bremnes Y; Mjaaland I
Acta Oncol; 2004; 43(2):186-9. PubMed ID: 15163168
[TBL] [Abstract][Full Text] [Related]
2. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Fumoleau P; Largillier R; Clippe C; Dièras V; Orfeuvre H; Lesimple T; Culine S; Audhuy B; Serin D; Curé H; Vuillemin E; Morère JF; Montestruc F; Mouri Z; Namer M
Eur J Cancer; 2004 Mar; 40(4):536-42. PubMed ID: 14962720
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
Bunnell C; Vahdat L; Schwartzberg L; Gralow J; Klimovsky J; Poulart V; Peck R; Thomas E
Clin Breast Cancer; 2008 Jun; 8(3):234-41. PubMed ID: 18650153
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Lee SH; Lee J; Park J; Park SH; Lee KE; Lee SI; Nam E; Park JO; Kim K; Jung CW; Park YS; Yoon SS; Kang WK; Lee MH; Park K; Im YH
Med Oncol; 2004; 21(3):223-31. PubMed ID: 15456949
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial.
Pajk B; Cufer T; Canney P; Ellis P; Cameron D; Blot E; Vermorken J; Coleman R; Marreaud S; Bogaerts J; Basaran G; Piccart M
Breast; 2008 Apr; 17(2):180-5. PubMed ID: 17976988
[TBL] [Abstract][Full Text] [Related]
6. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
Wang Z; Lu J; Leaw S; Hong X; Wang J; Shao Z; Hu X
Cancer Chemother Pharmacol; 2012 Feb; 69(2):515-22. PubMed ID: 21874317
[TBL] [Abstract][Full Text] [Related]
7. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
[TBL] [Abstract][Full Text] [Related]
9. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW
Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175
[TBL] [Abstract][Full Text] [Related]
10. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
Ito Y; Osaki Y; Tokudome N; Sugihara T; Takahashi S; Iwase T; Hatake K
Breast Cancer; 2009; 16(2):126-31. PubMed ID: 18807123
[TBL] [Abstract][Full Text] [Related]
12. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Thomas ES; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Pivot XB; Klimovsky JV; de Mendoza FH; Xu B; Campone M; Lerzo GL; Peck RA; Mukhopadhyay P; Vahdat LT; Roché HH
J Clin Oncol; 2007 Nov; 25(33):5210-7. PubMed ID: 17968020
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes.
Oksuzoglu B; Abali H; Hayran M; Yildirim N; Budakoglu B; Zengin N
Chemotherapy; 2008; 54(5):352-6. PubMed ID: 18728366
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes.
Kellokumpu-Lehtinen PL; Sunela K; Lehtinen I; Joensuu H; Sjöström-Mattson J;
Clin Breast Cancer; 2006 Dec; 7(5):401-5. PubMed ID: 17239265
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
Traina TA; Theodoulou M; Feigin K; Patil S; Tan KL; Edwards C; Dugan U; Norton L; Hudis C
J Clin Oncol; 2008 Apr; 26(11):1797-802. PubMed ID: 18398145
[TBL] [Abstract][Full Text] [Related]
16. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.
Blum JL; Dieras V; Lo Russo PM; Horton J; Rutman O; Buzdar A; Osterwalder B
Cancer; 2001 Oct; 92(7):1759-68. PubMed ID: 11745247
[TBL] [Abstract][Full Text] [Related]
17. [Experience with capecitabine in patients with anthracycline and/or taxane-resistant recurrent breast cancer].
Tagaya N; Nakagawa A; Mori S; Tachibana M; Kakihara Y; Hamada K; Suzuki N; Kubota K
Gan To Kagaku Ryoho; 2005 Aug; 32(8):1135-8. PubMed ID: 16121915
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program.
Pierga JY; Fumoleau P; Brewer Y; Zelek L; Martin D; Turpin FL; Goudier MJ; Gil-Delgado M; Baticle JL; Namer M; Chollet P; Sutherland W; Barats JC;
Breast Cancer Res Treat; 2004 Nov; 88(2):117-29. PubMed ID: 15564795
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine combined with weekly docetaxel in Chinese patients > 65 years with anthracycline-resistant metastatic breast cancer.
Wang HQ; Qian ZZ; Liu XM; Zhang HL; Li LF; Qiu LH; Hou Y; Zhou SY; Hao XS; Xie CH
Chin Med J (Engl); 2010 Nov; 123(22):3212-6. PubMed ID: 21163117
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
